WAKEFIELD, Mass., April 21, 2022 – PRESS RELEASE – Curaleaf Holdings Inc., a leading international provider of consumer products in cannabis, announced that it has been approved by the New Jersey Cannabis Regulatory Commission to commence adult-use cannabis sales. Starting April 21, 2022, the Curaleaf dispensary in Bellmawr will begin serving adult-use customers, with Edgewater Park and Bordentown to quickly follow.
During this period of expansion, patient care for individuals licensed under New Jersey’s Medical Marijuana Program will remain Curaleaf’s top priority at all New Jersey retail locations. In anticipation of increased demand, the company has tripled its cultivation capacity to ensure that medical patient supply is prioritized in the event of a product shortage. Additionally, Curaleaf will implement the following designated medical patient services for individuals who qualify:
Private consultation areasSecure online ordering systemsExpanded parking with dedicated spots for licensed medical patientsSeparate medical-patient only lines and check-outsTwo hours of operation every day dedicated solely to serving licensed medical patients, totaling 14 hours each week at each dispensary.
On April 21, adult-use consumers 21 and older can purchase up to 1 ounce of cannabis per day at Curaleaf Bellmawr, located at 640 Creek Road. Adult-use customers can choose from a product assortment that includes innovative products such as Select Squeeze, a fast-acting THC beverage enhancer, as well as traditional inhalable products including Curaleaf 3.5-gram flower jar, the Curaleaf 1-gram preroll and Curaleaf 0.5-gram vape cartridge. Shortly after launching, Curaleaf New Jersey will also offer its expanded assortment of award-winning Select products, including Select Bites and Select Elite vape cartridges, pending regulatory approvals.
“The launch of New Jersey’s adult-use marketplace is a major step forward for the cannabis industry and it is a privilege to be among the inaugural group of licensees that will mark the beginning of the state’s adult-use market,” Curaleaf CEO Joe Bayern said. “Our local teams look forward to building strong relationships with new consumers while deepening our ties with the medical community. Providing top-tier medical patient care remains our main priority and we have adopted considerable safeguards to make sure they can seamlessly access products to find relief. We thank you for your continued support as we join the state of New Jersey on this historic journey.”
As New Jersey’s cannabis market continues to evolve, Curaleaf will maintain a direct line of communication with members of the local medical cannabis community. For more information on Curaleaf’s locations, patient resources and products in New Jersey, please visit www.curaleaf.com/dispensary/new-jersey.